Suppression of Allograft Rejection with Soluble VEGF Receptor 2 Chimeric Protein in a Mouse Model of Corneal Transplantation
- 1 January 2016
- journal article
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 239 (1) , 81-88
Abstract
When a transparent cornea becomes opaque due to infectious diseases, trauma, or ophthalmic surgery, the impaired cornea is replaced with a donor cornea to improve visual function. In this corneal transplantation, the graft survival rate is comparatively high, partly because of lacking vascular and lymphatic vessel in cornea. However, the transplanted corneas sometimes become opaque if allograft rejection occurs. Suppression of allograft rejection is critical for favorable outcomes of corneal transplantation. The essential effects of endogenous monomeric soluble vascular endothelial growth factor receptors (VEGFRs) 1 and 2 have been reported in corneal angiogenesis and lymphangiogenesis. This study investigated the effects of dimeric soluble VEGFR2/Fc chimera protein on corneal allograft rejection for future clinical application. Allogeneic full-thickness corneal transplantation was performed in C57BL/6 to BALB/c mice. The recipients were treated by intrastromal injection of soluble VEGFR1/Fc chimera (sR1/Fc group), soluble VEGFR2/Fc chimera (sR2/Fc group), or human IgG1/Fc protein (IgG/Fc group) at 0, 7, and 14 days after surgery. Both hemangiogenesis and lymphangiogenesis were significantly suppressed in the corneas of the sR2/Fc group compared with the IgG/Fc group. All grafts failed due to corneal wound rupture in the sR1/Fc group. In the sR2/Fc group, respective donor-derived MHC class II(+)/CD11c(+) cells and CD11b-positive macrophage infiltration were reduced in the DLNs and the corneas showing a negative delayed-type hypersensitivity, compared with the IgG/Fc group. Our findings demonstrate that soluble VEGFR2/Fc chimera protein efficiently suppresses corneal allo-rejection, while reducing hemangiogenesis and lymhangiogenesis, and immune-competent cell-trafficking and may be a powerful tool for corneal allograft survival.Keywords
This publication has 18 references indexed in Scilit:
- Bevacizumab Application Delays Epithelial Healing in Rabbit CorneaInvestigative Ophthalmology & Visual Science, 2009
- Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growthNature Medicine, 2009
- Topical Bevacizumab in the Treatment of Corneal NeovascularizationArchives of Ophthalmology (1950), 2009
- Promotion of Graft Survival by Vascular Endothelial Growth Factor A Neutralization After High-Risk Corneal TransplantationArchives of Ophthalmology (1950), 2008
- Corneal avascularity is due to soluble VEGF receptor-1Nature, 2006
- Inhibition of Hemangiogenesis and LymphangiogenesisafterNormal-Risk Corneal Transplantation by Neutralizing VEGF Promotes Graft SurvivalInvestigative Ophthalmology & Visual Science, 2004
- Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunityNature Medicine, 2004
- Novel Expression of Vascular Endothelial Growth Factor Receptor (VEGFR)-3 and VEGF-C on Corneal Dendritic CellsThe American Journal of Pathology, 2003
- Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2002
- Angiogenesis in cancer and other diseasesNature, 2000